Abbisko Cayman Limited (2256.HK)
- Previous Close
7.830 - Open
7.680 - Bid 7.220 x --
- Ask 7.300 x --
- Day's Range
7.070 - 7.680 - 52 Week Range
2.730 - 8.980 - Volume
7,113,000 - Avg. Volume
6,459,189 - Market Cap (intraday)
4.855B - Beta (5Y Monthly) 1.22
- PE Ratio (TTM)
182.50 - EPS (TTM)
0.040 - Earnings Date Mar 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.10
Abbisko Cayman Limited, an investment holding company, engages in the research and development of pharmaceutical products in the People's Republic of China. The company develops Pimicotinib, which is in Phase III clinical trial for the treatment of tenosynovial giant cell tumor; Irpagratinib for the treatment of hepatocellular carcinoma; ABSK043 that is in Phase I clinical trial for the treatment of non-small cells lung cancer; and ABSK061 for the treatment of solid tumors. It also develops Fexagratinib, which is in Phase II clinical trial for the treatment of urothelial carcinoma; ABSK121, a small molecule FGFR inhibitor that targets both wild-type and mutations of FGFR1-3; ABSK112, an EGFR Exon20ins inhibitor with selectivity over wild-type EGFR and brain-penetration activity; Mavorixafor, an orally bioavailable CXCR4 modulator; and ABSK051, a small molecule CD73 inhibitor for the treatment of various tumor types, such as lung and pancreatic cancer. In addition, the company develops ABSK012, which is in Phase I clinical trial for treatment of soft tissue sarcoma; ABK131, a selective MTA-cooperative and brain-penetrant PRMT5 inhibitor; ABK3376, which is in Phase I clinical trial for the treatment of NSCLC harboring the EGFR-C797S mutation; and ABSK141, an orally bioavailable small-molecule KRAS-G12D inhibitor. Abbisko Cayman Limited was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
www.abbisko.comRecent News: 2256.HK
View MorePerformance Overview: 2256.HK
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2256.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2256.HK
View MoreValuation Measures
Market Cap
5.21B
Enterprise Value
3.13B
Trailing P/E
182.29
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.40
Price/Book (mrq)
2.48
Enterprise Value/Revenue
5.78
Enterprise Value/EBITDA
28.24
Financial Highlights
Profitability and Income Statement
Profit Margin
5.62%
Return on Assets (ttm)
-0.64%
Return on Equity (ttm)
1.44%
Revenue (ttm)
503.99M
Net Income Avi to Common (ttm)
28.3M
Diluted EPS (ttm)
0.040
Balance Sheet and Cash Flow
Total Cash (mrq)
2.01B
Total Debt/Equity (mrq)
1.24%
Levered Free Cash Flow (ttm)
73.63M